FDA's cancer drugs committee is anxious to approve new

FDA's cancer drugs committee is anxious to approve new drugs.

Quote:

[FDA's committee] has typically used some liberal assessments in reviewing new drugs, anxious to provide approvals in cases where docs want more options, or no drugs are currently approved .

But, Daiichi Sankyo "lost" the data for the 25th week of their clinical trial. FDA is not amused.

https://endpts.com/daiichi-sankyo-faces-fda-c...-drug-oks/